uniQure QURE
uniQure FY 2022: diluted EPS −$2.71
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001558370-23-002110
- Document
- 10-K
- Exhibit 4.1
- Warrants or notes
Key figures from this report
These are the numbers uniQure reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Diluted EPS−$2.71−138% from $7.04 in FY 202110-K income statement, on EDGAR
- Cash and cash equivalents$228.0M−59% from $556.3M in FY 202110-K balance sheet, on EDGAR
- Cash from operations−$145.1M−150% from $288.0M in FY 202110-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Phibro Animal Health PAHC public float $764M, Dec 31, 2025
- Pacira BioSciences PCRX public float $758M, Jun 30, 2025
- Cogent Biosciences COGT public float $773M, Jun 30, 2025
- Syndax Pharmaceuticals SNDX public float $799M, Jun 30, 2025
- Immunome IMNM public float $729M, Jun 30, 2025